Inclusion Criteria:  Adults aged ≥ 18 years (maximum 65 years old in India). Laboratory-confirmed diagnosis of SARS-CoV-2 infection within 10 days prior to randomisation. (Confirmation must be through Reverse Transcription Polymerase Chain Reaction [RT-PCR] method) Intended for hospital admission for management of COVID-19. Patients with moderate (respiratory rate of ≥ 24/minute or SPO2: 90% to ≤ 93% on room air) or severe (respiratory rate of ≥ 30/minute or SPO2: <90% on room air) COVID-19. Systolic Blood Pressure (SBP) ≥ 120 mmHg OR SBP ≥ 115 mmHg and currently treated with a non-RAASi BP lowering agent that can be ceased. Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments. Documented informed consent.  Exclusion Criteria:  Currently treated with an ACEi, ARB or aldosterone antagonist, aliskiren, or ARNi Intolerance of ARBs Serum potassium >5.5 mmol/L An estimated Glomerular Filtration Rate (eGFR) <30ml/min/1.732m Known biliary obstruction, known severe hepatic impairment (Child-Pugh-Turcotte score 10-15) Pregnancy, lactation, or inadequate contraception. Participation in a study of a novel investigational product within 28 days prior to randomisation. Plans to participate in another study of a novel investigational product during this study.